178 related articles for article (PubMed ID: 28923059)
1. Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling.
Mei Y; Du Z; Hu C; Greenwald NF; Abedalthagafi M; Agar NYR; Dunn GP; Bi WL; Santagata S; Dunn IF
Cell Commun Signal; 2017 Sep; 15(1):34. PubMed ID: 28923059
[TBL] [Abstract][Full Text] [Related]
2. Chrysophanol inhibits the osteoglycin/mTOR and activats NF2 signaling pathways to reduce viability and proliferation of malignant meningioma cells.
Wang J; Lv P
Bioengineered; 2021 Dec; 12(1):755-762. PubMed ID: 33622177
[TBL] [Abstract][Full Text] [Related]
3. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
Beauchamp RL; Erdin S; Witt L; Jordan JT; Plotkin SR; Gusella JF; Ramesh V
J Biol Chem; 2021; 296():100157. PubMed ID: 33273014
[TBL] [Abstract][Full Text] [Related]
4. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types.
James MF; Stivison E; Beauchamp R; Han S; Li H; Wallace MR; Gusella JF; Stemmer-Rachamimov AO; Ramesh V
Mol Cancer Res; 2012 May; 10(5):649-59. PubMed ID: 22426462
[TBL] [Abstract][Full Text] [Related]
5. NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
James MF; Han S; Polizzano C; Plotkin SR; Manning BD; Stemmer-Rachamimov AO; Gusella JF; Ramesh V
Mol Cell Biol; 2009 Aug; 29(15):4250-61. PubMed ID: 19451225
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 regulates tumor proliferation and T-cell function in NF2-associated meningiomas.
Wang Y; Zhang C; Yan M; Ma X; Song L; Wang B; Li P; Liu P
CNS Neurosci Ther; 2024 Jun; 30(6):e14784. PubMed ID: 38828669
[TBL] [Abstract][Full Text] [Related]
7. The miR-1290/OGN axis in ovarian cancer-associated fibroblasts modulates cancer cell proliferation and invasion.
Jiang B; Xiao S; Zhang S; Xiao F
J Ovarian Res; 2024 Feb; 17(1):52. PubMed ID: 38402185
[TBL] [Abstract][Full Text] [Related]
8. Crispr/Cas-based modeling of NF2 loss in meningioma cells.
Waldt N; Kesseler C; Fala P; John P; Kirches E; Angenstein F; Mawrin C
J Neurosci Methods; 2021 May; 356():109141. PubMed ID: 33753124
[TBL] [Abstract][Full Text] [Related]
9.
Das A; Martinez Santos JL; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
Cancer Invest; 2020 Jul; 38(6):349-355. PubMed ID: 32441531
[No Abstract] [Full Text] [Related]
10. A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.
Beauchamp RL; James MF; DeSouza PA; Wagh V; Zhao WN; Jordan JT; Stemmer-Rachamimov A; Plotkin SR; Gusella JF; Haggarty SJ; Ramesh V
Oncotarget; 2015 Jul; 6(19):16981-97. PubMed ID: 26219339
[TBL] [Abstract][Full Text] [Related]
11. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
[TBL] [Abstract][Full Text] [Related]
12. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
[TBL] [Abstract][Full Text] [Related]
13. RNAi-mediated downregulation of radiation-induced MMP-9 leads to apoptosis via activation of ERK and Akt in IOMM-Lee cells.
Gogineni VR; Kargiotis O; Klopfenstein JD; Gujrati M; Dinh DH; Rao JS
Int J Oncol; 2009 Jan; 34(1):209-18. PubMed ID: 19082492
[TBL] [Abstract][Full Text] [Related]
14. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
Angus SP; Oblinger JL; Stuhlmiller TJ; DeSouza PA; Beauchamp RL; Witt L; Chen X; Jordan JT; Gilbert TSK; Stemmer-Rachamimov A; Gusella JF; Plotkin SR; Haggarty SJ; Chang LS; Johnson GL; Ramesh V;
Neuro Oncol; 2018 Aug; 20(9):1185-1196. PubMed ID: 29982664
[TBL] [Abstract][Full Text] [Related]
15. Cucurbitacin I blocks cerebrospinal fluid and platelet derived growth factor-BB stimulation of leptomeningeal and meningioma DNA synthesis.
Johnson MD; O'Connell MJ; Walter K
BMC Complement Altern Med; 2013 Nov; 13():303. PubMed ID: 24188277
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment by octreotide and everolimus: Octreotide enhances inhibitory effect of everolimus in aggressive meningiomas.
Graillon T; Defilles C; Mohamed A; Lisbonis C; Germanetti AL; Chinot O; Figarella-Branger D; Roche PH; Adetchessi T; Fuentes S; Metellus P; Dufour H; Enjalbert A; Barlier A
J Neurooncol; 2015 Aug; 124(1):33-43. PubMed ID: 26015296
[TBL] [Abstract][Full Text] [Related]
17. Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas.
Dickinson PJ; Surace EI; Cambell M; Higgins RJ; Leutenegger CM; Bollen AW; LeCouteur RA; Gutmann DH
Vet Pathol; 2009 Sep; 46(5):884-92. PubMed ID: 19429976
[TBL] [Abstract][Full Text] [Related]
18. An Essential Role for the Tumor-Suppressor Merlin in Regulating Fatty Acid Synthesis.
Stepanova DS; Semenova G; Kuo YM; Andrews AJ; Ammoun S; Hanemann CO; Chernoff J
Cancer Res; 2017 Sep; 77(18):5026-5038. PubMed ID: 28729415
[TBL] [Abstract][Full Text] [Related]
19. Ganoderic acid A/DM-induced NDRG2 over-expression suppresses high-grade meningioma growth.
Das A; Alshareef M; Henderson F; Martinez Santos JL; Vandergrift WA; Lindhorst SM; Varma AK; Infinger L; Patel SJ; Cachia D
Clin Transl Oncol; 2020 Jul; 22(7):1138-1145. PubMed ID: 31732915
[TBL] [Abstract][Full Text] [Related]
20. Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathway.
Hu X; Li YQ; Li QG; Ma YL; Peng JJ; Cai SJ
J Exp Clin Cancer Res; 2018 Mar; 37(1):41. PubMed ID: 29499765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]